rs17321515 — TRIB1

TRIB1 rs17321515 — A Lipid and Sleep Regulator at the 8q24 Locus

The TRIB1 gene¹¹ TRIB1 gene
tribbles pseudokinase 1, a regulatory scaffold protein controlling hepatic lipid metabolism via degradation of lipogenic transcription factors sits at one of the most robustly replicated lipid loci in the human genome. The rs17321515 variant, located approximately 30–44 kb downstream of TRIB1 on chromosome 8q24, is one of the most-studied SNPs at this locus. Unlike the companion variant rs2954021 (where G raises triglycerides), rs17321515 works in reverse orientation: here the A allele is the risk allele, raising triglycerides, LDL cholesterol, and total cholesterol. The two variants are in strong linkage disequilibrium in many populations, but rs17321515 has accumulated an independent literature — particularly in Asian and European cohorts — and carries a notable additional association with sleep duration that rs2954021 does not share.

The Mechanism

The rs17321515 locus overlaps with a region now called TRIBAL²² TRIBAL
TRIB1-associated locus, a long noncoding RNA whose promoter region harbors lipid- associated regulatory variants. The closely linked SNP rs2001844 (D'=1, r²=0.98 with rs17321515) lies within the TRIBAL promoter and functions as an eQTL³³ eQTL
expression quantitative trait locus — a genetic variant that influences how much of a nearby gene is expressed for TRIB1 in blood. By modulating TRIBAL expression and TRIB1 levels, variants at this locus alter the activity of the TRIB1–COP1–C/EBPα axis that governs hepatic de novo lipogenesis⁴⁴ hepatic de novo lipogenesis
the liver's conversion of excess carbohydrates into triglycerides exported as VLDL particles. The A allele at rs17321515 appears to increase hepatic lipid production output, raising circulating triglycerides and modifying LDL particle composition.

The sleep connection arises because TRIB1 expression in blood increases approximately 1.6-fold after sleep restriction and falls during recovery⁵⁵ TRIB1 expression in blood increases approximately 1.6-fold after sleep restriction and falls during recovery
demonstrating a direct, bidirectional link between TRIB1 activity and sleep homeostasis. The A allele of rs17321515 was associated with both elevated total cholesterol and longer total sleep time in the same Finnish population sample, suggesting the variant influences a shared biological pathway connecting circadian metabolism and lipid regulation.

The Evidence

The TRIB1 locus was first identified as a triglyceride-associated region by Kathiresan et al. (2008)⁶⁶ Kathiresan et al. (2008)
Six new loci associated with blood LDL, HDL, or triglycerides — 8,816 discovery + 18,554 replication subjects, Nature Genetics, and was subsequently confirmed in the Global Lipids Genetics Consortium (2013)⁷⁷ Global Lipids Genetics Consortium (2013)
the largest lipid GWAS at the time, 188,578 participants across European, East Asian, South Asian, and African ancestry, Nature Genetics. The rs17321515 variant specifically has been validated in multiple independent cohorts.

A large Chinese Han population study⁸⁸ Chinese Han population study
1,332 CHD cases and 2,811 controls found the A allele significantly associated with elevated triglycerides (GG = 1.56 mmol/L, GA = 1.65 mmol/L, AA = 1.69 mmol/L; p for trend = 0.005 in additive model) and CHD (AA genotype OR = 1.58, 95% CI: 1.13–2.20, p = 0.01 overall; effects strongest in males and smokers). A Chinese NAFLD case-control study⁹⁹ Chinese NAFLD case-control study
146 NAFLD cases vs. 175 healthy controls found the GA + AA genotype associated with nearly doubled NAFLD risk (OR = 1.885; 95%CI: 1.157–3.070; adjusted for age, gender, BMI: OR = 2.240, 95%CI: 1.196–4.197).

The sleep association was discovered in a Finnish population study¹⁰¹⁰ Finnish population study
6,334 adults with replication in 2,189 twins — the A allele was associated with significantly longer total sleep time (β = +0.081 h per allele at meta-analysis, p = 8.1×10⁻⁶), establishing rs17321515 as one of the few common variants with pleiotropic effects spanning lipid metabolism and sleep biology.

A 2023 meta-analysis¹¹¹¹ 2023 meta-analysis
108,831 individuals confirmed that A allele carriers have higher LDL-C and total cholesterol and elevated CAD risk, with effects most pronounced in Asian populations.

Practical Actions

For A allele carriers, the metabolic picture mirrors that of the shipped rs2954021-G risk genotype: the core triglyceride-lowering strategy focuses on reducing hepatic substrate load. Limiting added sugars (especially fructose, the primary substrate for de novo lipogenesis), restricting refined carbohydrates, moderating alcohol, and increasing omega-3 fatty acid intake (EPA + DHA at 2–4 g/day) are the highest-yield interventions. A fasting lipid panel with triglycerides and LDL-C establishes baseline. If LDL-C is also elevated — as the meta-analysis evidence suggests is more likely for A carriers — considering ApoB measurement and direct LDL testing provides a more complete picture than calculated LDL alone.

The sleep association adds a dimension not captured by rs2954021: A allele carriers tend toward longer habitual sleep, and the genetic signal connecting their TRIB1 variant to both lipid dysregulation and sleep duration is biologically unified. This does not mean longer sleep is harmful — rather, it reflects shared TRIB1-mediated circadian-metabolic regulation.

The NAFLD association is particularly relevant for AA homozygotes, who carry two copies of the A allele and face the highest lipid accumulation risk. Liver enzyme monitoring (ALT, AST) and fructose restriction are especially important for this genotype.

Interactions

rs17321515 and rs2954021 are in strong linkage disequilibrium in most populations and both tag the same TRIB1 regulatory locus. Individuals carrying risk alleles at both SNPs are likely carrying the same underlying haplotype rather than two independent effects. The more informative interaction is with GCKR rs1260326 — glucokinase regulatory protein variants independently modulate hepatic de novo lipogenesis through a complementary pathway, and combined TRIB1 + GCKR risk alleles produce additive hepatic lipid burden. Carriers of multiple triglyceride-raising variants across the TRIB1/GCKR/APOB loci face cumulative lipid risk warranting a broader lipid panel (including ApoB).